Proteomics: A Tool In Future

 

Pallavi Salve*, Rupali Kirtawade, Deepali Gharge, Pandurang Dhabale and Kishor Burade

Govt. College of Pharmacy, Karad.

 

 

ABSTRACT

Scientists are very interested in proteomics because it gives a much better understanding of an organism than genomics. First, the level of transcription of a gene gives only a rough estimate of its level of expression into a protein. Whole Genome Sequence gives complete proteins contain, but does not show how proteins function or biological processes occur. Proteomics gives large-scale study of proteins, particularly their structures and functions. Proteomics is a term in the study of genetics which refers to all the proteins expressed by a genome; proteomics involves the identification of proteins in the body and the determination of their role in physiological and pathphysiological functions. The term "proteomics" was coined to make an analogy with genomics, the study of the genes. The word "proteome" is a blend of "protein" and "genome". Proteomics technologies are of major three types Expression Proteomics, Structural Proteomics, Functional Proteomics.  Proteomics is applied in various fields like Tumor Metastasis, renal disease diagnosis, Neurology etc. But proteomic technologies hold great promise in the search for clinically useful protein biomarkers for the early detection, diagnosis and prognosis of cancer and for monitoring response to therapy.

 

 

KEY WORDS: Proteomics, genomics, Genome, proteome

 

 

INTRODUCTION

After genomics, proteomics is often considered the next step in the study of biological systems. It is much more complicated than genomics mostly because while an organism's genome is more or less constant, the proteome differs from cell to cell and from time to time. This is because distinct genes are expressed in distinct cell types. This means that even the basic set of proteins which are produced in a cell needs to be determined.

 

In the past this was done by mRNA analysis, but this was found not to correlate with protein content.1,2 It is now known that mRNA is not always translated into protein3 and the amount of protein produced for a given amount of mRNA depends on the gene it is transcribed from and on the current physiological state of the cell. Proteomics confirms the presence of the protein and provides a direct measure of the quantity present.

 

Proteomics :

Proteomics is the large-scale study of proteins, particularly their structures and functions4,5.Proteins are vital parts of living organisms, as they are the main components of the physiological metabolic pathways of cells. The term "proteomics" was first coined in 19976 to make an analogy with genomics, the study of the genes. The word "proteome" is a blend of "protein" and "genome", and was coined by Marc Wilkins in 1994 while working on the concept as a PhD student.7,8 . The proteome is the entire complement of proteins,7 including the modifications made to a particular set of proteins, produced by an organism or system. This will vary with time and distinct requirements, or stresses, that a cell or organism undergoes.

 

 


The dream of having genomes completely sequenced is now a reality. The complete sequence of many genomes including the human one is known. However, the understanding of probably half a million human proteins encoded by less than 30'000 genes is still a long way away and the hard work to unravel the complexity of biological systems is yet to come. A new fundamental concept called proteome (PROTEin complement to a genOME) has recently emerged that should drastically help to unravel biochemical and physiological mechanisms of complex multivariate diseases at the functional molecular level. The discipline of proteomics has been initiated to complement physical genomic research. Proteomics can be defined as the qualitative and quantitative comparison of proteomes under different conditions to further unravel biological processes.13

 

Some Definitions in Proteomics:

1] Genome:

One complete set of genes in an organism (a haploid set)10,11

Except for occasional unrepaired damage to its DNA (= mutations), the genome is fixed.

 

2] Transcriptome:

The most common definition: All the messenger RNA (mRNA) molecules transcribed from the genome. Varies with the differentiated state of the cell and the activity of the transcription factors that turn gene transcription on (and off). Speaking strictly, one would define the transcriptome as all the RNA molecules — which includes a wide variety of untranslated, nonprotein-encoding RNA — transcribed from the DNA of the genome. It is now thought that 70% of our DNA (including vast amounts of "junk" DNA) is transcribed into RNA although only 1.5% of this is messenger RNA for protein synthesis10

 

3] Proteome:

Two popular definitions:

·        All the proteins that can be synthesized by the cell.10,11,12

·        All the proteins synthesized by a particular cell at a particular time.

The proteome is the protein complement of the genome . It is quite a bit more complicated than the genome because a single gene can give rise to a number of different proteins through

·        alternative splicing of the pre-messenger RNAs;

·        RNA editing of the pre-messenger RNAs;

·        attachment of carbohydrate residues to form glycoproteins,

·        addition of phosphate groups to some of the amino acids in the protein.

While we humans may turn out to have only 25 to 30 thousand genes, we probably make at least 10 times that number of different proteins. More than 50% of our genes produce pre-mRNAs that are alternatively-spliced.

 

The study of proteomics is important because proteins are responsible for both the structure and the functions of all living things. Genes are simply the instructions for making proteins. It is proteins that make life.9,25

 

4] Metabolome:

All the metabolic machinery, e.g., enzymes, coenzymes - small metabolites, like, the intermediates in glycolysis and cellular respiration, nucleotides, present in a cell at a given time. Varies with the differentiated state of the cell and its current activities.9,10

 

Study of Proteomics:

1.      Isolate a homogeneous population of cells (e.g., yeast cells that have just been switched from glucose to galactose as their energy source).

2.      Extract the contents of the cells and separate the mix of proteins from other components.

3.      Separate the proteins in the mix by two-dimensional (2D) gel electrophoresis. This separates the proteins

o   in one dimension by their electrical charge;

o   in the second dimension by their size.

(The procedure is analogous to that used in paper chromatography.)

4.      Stain the gel to visualize the various spots of protein.

5.      Punch out a spot.

6.      Add a protease (e.g., trypsin) to digest the protein in that spot into a mix of peptides.

7.      Run the mix through a mass spectrometer, which will separate the peptides into sharply-defined peaks.

8.      Run the resulting data through a database of all known proteins (that have been digested with the same enzyme) to see if you can find a match.9,14,15

 

What if there is no match; that is, you have stumbled on an unknown protein?

1. Isolate individual peptides from your mix and run one through a mass spectrometer that has been modified to

o   first randomly break the peptide into a mix of fragments containing one, two, etc. amino acids

o   then measure the mass of each fragment.

2.Enter the resulting data into a database that matches the mass data with known pairs, triplets, etc. of amino acids.

3.With the aid of overlaps, assemble the fragments to reveal the entire sequence of the peptide.

4."Back-translate" the amino acid sequence to determine what sequence of nucleotides in DNA could encode that peptide.

5.Search the genome database for an open reading frame (ORF) that contains that sequence.

6.Translate that ORF to get the entire amino acid sequence of your protein.9,14,15

 

Analysis of Protein Function:

1. Affinity Chromatography:

·        Attach the protein whose partners to find to a solid matrix in a glass column.

·        Run a solution containing a mix of possible partners through the column.

·        Those that can bind to the target will stick; the others will flow through.

·        Pass a buffer through the column which will weaken the binding interactions.

·        The partners will wash out and can be identified16,17

 

2. The Yeast Two-Hybrid System:

·        The budding yeast, Saccharomyces cerevisiae, provides an excellent tool for discovering protein partners. It can easily be transformed with plasmids containing foreign DNA sequences; that is, recombinant DNA.

·        It can live in either the haploid or diploid condition.

·        Haploid cells can fuse to form diploid cells if they are of opposite mating types (designated a and α).

The two-hybrid system also takes advantage of the fact that transcription factors (proteins) usually contain

·        a DNA-binding domain: a region that binds to a specific sequence of DNA in the promoter of the gene they turn on;

·        an activation domain: a region that is needed to activate the assembly of the other components of the transcription apparatus16,18

 

3. Phage Display:

This method exploits:

·        a DNA bacteriophage that infects E. coli;

·        its ability to remain infectious even if one of its coat proteins contains segments of a foreign protein.18

 

4. Protein Chips:

Protein chips work on much the same principle as DNA chips.

·        A library of hundreds or even thousands of different proteins from your organism are spotted individually in a known location on a chip.

·        The chip is flooded with a solution of the protein whose partners you seek.

·        Any proteins on the chip that are potential binding partners will bind your test protein.

·        Adding a fluorescent "tag" permits these to be identified.

Although simple in principle, protein chips are far more difficult to work with than DNA chips because proteins

·        vary enormously in their chemistry (e.g., hydrophobic vs hydrophilic);

·        bind to each other by several types of noncovalent interactions.

Fragments of DNA, in contrast, vary only in their nucleotide sequence and all bind their partners by simple Watson-Crick base pairing16 .

 

Three-Dimensional (3D) Structure of Protein:

The clearest picture of how different proteins interact with one another to form functional complexes will come from determining the 3D structure of the complex. There are two methods:

·        X-ray crystallography;

·        nuclear magnetic resonance (NMR) spectroscopy.

X-ray crystallography requires that you be able to crystallize the protein. This is often a difficult task and especially difficult for complexes of two or more proteins.

Here are some links to 3D images of proteins.

·        the glucocorticoid receptor

·        the tryptophan repressor

Note that although in both cases the proteins are binding to DNA, they are also binding to each other (as homodimers). NMR spectroscopy has been especially useful in producing 3D images of proteins that cannot be crystallized.

 

The following are the major types of proteomics:

Expression Proteomics:

This is the qualitative and quantitative study of the expression of total proteins under two different conditions. For example, expression proteomics of normal cells and diseased cells can be compared to understand the protein that is responsible for the diseased state or the protein that is expressed due to disease. Using this method disease-specific protein can be identified and characterized by comparing the protein-expression profile of the entire proteome or of the subproteome between the two samples. 26,28

 

For example, tumor tissue samples from a cancer patient and the same type of tissue from a normal person can be analyzed for differential protein expression. Using two-dimensional gel electrophoresis, mass spectrometry combined with chromatography and microarray techniques, additional proteins that are expressed in the cancer tissues or the proteins, which are absent, or those, which are over expressed and under-expressed can be identified and characterized. Identification of these proteins will give valuable information about the molecular biology of tumor formation.27

 

Structural Proteomics:

Structural proteomics, as the name indicates, is about the structural aspects, including the three-dimensional shape and structural complexities, of functional proteins. This includes the structural prediction of a protein when its amino acid sequence is determined directly by sequencing or from the gene with a method called homology modeling. This can be carried out by doing a homology search and computational methods of protein structural studies and predictions. 29,30

 

Apart from this, structural proteomics can map out the structure and function of protein complexes present in a specific cellular organelle.31 It is possible to identify all the proteins present in a complex system such as ribosomes, membranes, or other cellular organelles and to characterize or predict all the proteins and protein interactions that can be possible between these proteins and protein complexes. Structural proteomics of a specific organelle or protein complex can give information regarding supra-molecular assemblies and their molecular architecture in cells, organelles, and in molecular complexes.32

 

Functional Proteomics:

This is an assembly type of proteomic method to analyze and understand the properties of macromolecular networks involved in the life activities of a cell. With these methods it will be possible to identify specific protein molecules and their role in individual metabolic activities and their contribution to the metabolic network that operates in the system. This forms one of the major objectives of functional proteomics. For example, the recent elucidation of the protein network involved in the functioning of a nuclear pore complex has led to the identification of novel proteins involved in the translocation of macromolecules between the cytoplasm and nucleus through these complex pores.31

 

Functional proteomics is yielding large databases of interacting proteins, and extensive pathway maps of these interactions are being scored and deciphered by novel high-throughput technologies. However, traditional methods of screening have not been very successful in identifying protein-protein interactionsand their inhibitors. The identification and measurement of changes in the concentration of specific proteins that cells make as a result of their genetic response to specific toxicants, and how these proteins are related to each other and to the specific biological condition of the cell, also fall under functional proteomics.33

 

 

Applications of proteomics:

1] Application of proteomics for discovery of protein biomarkers:

Biomarkers of drug efficacy and toxicity are becoming a key need in the drug development process. Mass spectral-based proteomic technologies are ideally suited for the discovery of protein biomarkers in the absence of any prior knowledge of quantitative changes in protein levels. The success of any biomarker discovery effort will depend upon the quality of samples analysed, the ability to generate quantitative information on relative protein levels and the ability to readily interpret the data generated. This review will focus on the strengths and weaknesses of technologies currently utilized to address these issues.20,24

 

2] Application of Proteomics in the Study of Tumor Metastasis:

Tumor metastasis is the dominant cause of death in cancer patients. However, the molecular and cellular mechanisms underlying tumor metastasis are still elusive. The identification of protein molecules with their expressions correlated to the metastatic process would help to understand the metastatic mechanisms and thus facilitate the development of strategies for the therapeutic interventions and clinical management of cancer. Proteomics is a systematic research approach aiming to provide the global characterization of protein expression and function under given conditions. Proteomic technology has been widely used in biomarker discovery and pathogenetic studies including tumor metastasis. This article provides a brief review of the application of proteomics in identifying molecular factors in tumor metastasis process. The combination of proteomics with other experimental approaches in biochemistry, cell biology, molecular genetics and chemistry, together with the development of new technologies and improvements in existing methodologies will continue to extend its application in studying cancer metastasis.34

 

3] Application of Proteomics Technology to the Field of Neurotrauma:

Near-completion of the Human Genome Project has stimulated scientists to begin looking for the next step in unraveling normal and abnormal functions within biological systems. Consequently, there is new focus on the role of proteins in these processes. Proteomics is a burgeoning field that may provide a valuable approach to evaluate the post-traumatic central nervous system (CNS). Although we cannot provide a comprehensive assessment of all methods for protein analysis, this report summarizes some of the newer proteomic technologies that have propelled this field into the limelight and that are available to most researchers in neurotrauma.35

 

4] Application of proteomics in renal disease diagnosis:

In the diagnosis and treatment of kidney disease, a major priority is the identification of disease-associated biomarkers. Proteomics, with its high-throughput and unbiased approach to the analysis of variations in protein expression patterns (actual phenotypic expression of genetic variation), promises to be the most suitable platform for biomarker discovery. Combining such classic analytical techniques as two-dimensional gel electrophoresis with more sophisticated techniques, such as MS, has enabled considerable progress to be made in cataloguing and quantifying proteins present in urine and various kidney tissue compartments in both normal and diseased physiological states. Despite these accomplishments, there remain a number of important challenges that will need to be addressed, (i) completely defining the proteome in the various biological compartments (e.g.tissues, serum and urine) in both health and disease, which presents a major challenge given the dynamic range and complexity of such proteomes (ii) achieving the routine ability to accurately and reproducibly quantify proteomic expression profiles; and (iii) developing diagnostic platforms that are readily applicable and technically feasible for use in the clinical setting that depend on the fruits of the preceding two tasks to profile multiple disease biomarkers.21,23

 

5] The Application of Proteomics in Neurology:

In neurology and neuroscience, many applications of proteomics have involved neurotoxicology and neurometabolism, as well as in the determination of specific proteomic aspects of individual brain areas and body fluids in neurodegeneration. Investigation of brain protein groups in neurodegeneration, such as enzymes, cytoskeleton proteins, chaperones, synaptosomal proteins and antioxidant proteins, is in progress as phenotype related proteomics. The concomitant detection of several hundred proteins on a gel provides sufficiently comprehensive data to determine a pathophysiological protein network and its peripheral representatives. The rapid spread of proteomics technology, which principally consists of twodimensional gel electrophoresis (2-DE) with in-gel protein digestion of protein spots and identification by massspectrometry, has provided an explosive amount of results.20

 

Alzheimer's disease:

In Alzheimer’s disease, elevations in beta secretase create amyloid/beta-protein, which causes plaque to build up in the patient's brain, which is thought to play a role in dementia.[citation needed] Targeting this enzyme decreases the amyloid/beta-protein and so slows the progression of the disease. A procedure to test for the increase in amyloid/beta-protein is immunohistochemical staining, in which antibodies bind to specific antigens or biological tissue of amyloid/beta-protein.20

 

6] Proteomics in Urological Cancer Research:

Proteomic analysis allows the comparison of the proteins present in a diseased tissue sample with the proteins present in a normal tissue sample. Any proteins, which have been altered either quantitatively or qualitatively between the normal and diseased sample are likely to be associated with the disease process. These proteins can be identified and may be useful as diagnostic markers for the early detection of the disease or prognostic markers to predict the outcome of the disease or they may be used as drug targets for the development of new therapeutic agents. The purpose of this review is to outline the principle technologies involved in proteome analysis and indicate current and potential future applications of proteomic analysis in urological cancer research.23

 

Initially, researchers are concentrating on ovarian and prostate cancers, which usually are not detected in early stages when the cancer is progressing without symptoms. By using proteomics for early detection, tumors may be treated before they spread (metastasize) to other parts of the body. Scientists also are studying the most common, solid human tumors including breast, colon, lung, and pancreatic cancers.20,23

 

7] Application of Proteomics in Cardiovascular research:

The development of proteomics is a timely one for cardiovascular research. Analyses at the organ, sub cellular, and molecular levels have revealed dynamic, complex, and subtle intracellular processes associated with heart and vascular disease. The power and flexibility of proteomic analyses, which facilitate protein separation, identification, and characterization, should hasten our understanding of these processes at the protein level. Properly applied, proteomics provides researchers with cellular protein “inventories” at specific moments in time, making it ideal for documenting protein modification due to a particular disease, condition, or treatment. This is accomplished through the establishment of species- and tissue-specific protein databases, providing a foundation for subsequent proteomic studies.20,24

 

Heart disease is commonly assessed using several key protein based biomarkers. Standard protein biomarkers for CVD include interleukin-6, interleukin-8, serum amyloid A protein, fibrinogen, and troponins. cTnI cardiac troponin I increases in concentration within 3 to 12 hours of initial cardiac injury and can be found elevated days after an acute myocardial infarction. A number of commercial antibody based assays as well as other methods are used in hospitals as primary tests for acute MI.24

 

8] Application of proteomics to diabetes research:

Proteomics is the investigation of all the proteins and their various modifications making up a system, be that a cell, tissue or organism. The techniques involved in proteomics allow the global screening of complex samples of proteins and provide qualitative and quantitative evidence of altered protein expression. This lends itself to the investigation of the molecular mechanisms underpinning disease processes and the effects of treatment. This review describes the main techniques of proteomics and how they have begun to be applied to diabetes research.22

 

CONCLUSION:

Proteome is a complement of proteins expressed in a cell at given time and proteomics means global analysis of this protein complement. Detailed and comprehensive characterization of proteins is a major goal of proteomics. This goal has become more realistic today with the latest high-resolution mass spectrometers capable of faster sequencing in a high-throughput fashion and with the emergence of new techniques such as protein and peptide microarrays. A promising area for discovery is the application of these advanced mass spectrometric and other quantitative proteomic methodologies to laboratory diagnosis.

 

REFERENCES:

1.       Simon R., et al ,"Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models". Bioinformatics. 2008, 24 : 2894–2900. doi:10.1093/bioinformatics/btn553. PMID 18974169.

2.       Vikas D, et al.. "New frontiers in proteomics research: A perspective". International Journal of Pharmaceutics.2005,299:1–18.

3.       Buckingham, Steven 5. "The major world of microRNAs". Micrornas 2003, 01-14

4.       Anderson N, Anderson N.. "Proteome and proteomics: new technologies, new concepts, and new words". Electrophoresis 1998,19 :1853–61.

5.       Blackstock W, Weir M. "Proteomics: quantitative and physical mapping of cellular proteins". Trends Biotechnol. 1999, 17 : 121–7.

6.       P. James. "Protein identification in the post-genome era: the rapid rise of proteomics.". Quarterly reviews of biophysics.1997,30: 279–331.

7.       Marc R. Wilkins,. "From Proteins to Proteomes: Large Scale Protein Identification by Two-Dimensional Electrophoresis and Arnino Acid Analysis". Nature Biotechnology.1996, 14 : 61–65.

8.       Wilkins, Marc R., et al. New Frontiers in Functional Genomics. Proteome Research New York: Springer-Verlag, 1997.

9.       Belhajjame, K. et al. Proteome Data Integration: Characteristics and Challenges. Proceedings of the UK e-Science All Hands Meeting, ISBN 1-904425-53-4, September 2005, Nottingham, UK.

10.     Liebler DC. Introduction to proteomics: tools for the new biology. 2002, 7: 89603-992.

11.     Wilkins MR, Williams KL, Appel RD, Hochstrasser DF. Proteome Research: New Frontiers in Functional Genomics , Principles and Practice. 1997, 3-540-62753-7.

12.     Twyman RM. Principles Of Proteomics .Advanced Text Series. 2004, 1-85996-273-4.

13.     Fuchs, Jurgen, and Maurizio Podda, editors. Encyclopedia of Medical Genomics and Proteomics. New York: Dekker, 2005

14.     Aebersold R.,  Mann M. Mass Spectrometry-Based Proteomics. Nature.2003, 422: 198–207.

15.     Zhu, W., et al. 'Detection of Cancer-Specific Markers Amid Massive Mass Spectral Data.' Proceedings of the National Academy of Sciences . 2003,100: 14666–71.

16.     Zhu H, et al. Global analysis of protein activities using proteome chips. Science . 2001,293:2101–2105

17.     Arora PS,.Comparative evaluation of two two-dimensional gel electrophoresis image analysis software applications using synovial fluids from patients with joint disease. J Orthop Sci 2005,10,2: 160–6

18.     Jorg von Hagen, VCH-Wiley  Proteomics Sample Preparation. 2008,978-3-527-31796-7

19.     Westermeier, R. and T. Naven.. Proteomics in practice: a laboratory manual of proteome analysis. 2002, 3-527-30354-5.

20.     Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006,129 ,Pt 11: 3042–50.

21.     Perroud B, Lee J, Valkova N, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006. 5: 64.

22.     Yohannes E, et al  . Proteomics analysis identifies molecular targets related to diabetes mellitus-associated bladder dysfunction. Mol. Cell Proteomics.  2008,7: 1270–85.

23.     Rogers M, et al.. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 2003, 63: 6971–83.

24.     Vasan R., Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation . 2006, 113 : 2335–62.

25.     Weaver R., Molecular biology , 3rd ed, New York: McGraw-Hill. 2005.

26.     Karp N, et al, Impact of replicate types on proteomic expression analysis. Journal of proteome research. 2005, 4:1867-71

27.     Karp N, Lilley KS., Maximising sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes,. Proteomics. 2005 , 5:3105-15.

28.     Martins D, et al., The untiring search for the most complete proteome representation: reviewing the methods, Brief Funct Genomic Proteomic. 2008, 7:312-21.

29.     Dobrovetsky E, et al.,  A robust purification strategy to accelerate membrane proteomics. Methods. 2007, 41:381-7.

30.     Watson J.,  Towards fully automated structure-based function prediction in structural genomics: a case study. J Mol Biol. 2007, 13;367:1511-22.

31.     Norin M, Sundström M..Structural proteomics: developments in structure-to-function predictions,Trends Biotechnol. 2002 , 20:79-84.

32.     Yakunin A., et al, Structural proteomics: a tool for genome annotation. Curr Opin Chem Biol. 2004, 8:42-8.

33.     Frederic C., Functional Proteomics Mapping of a Human Signaling Pathway. Genome Res.,2004,14: 24-1332.

34.     Cai Z, Chiu JF, He QY. Application of proteomics in the study of tumor metastasis. Genomics Proteomics Bioinformatics. 2004, 2:152-66.

35.     Nancy Denslow,et al.,  Application of Proteomics Technology to the Field of Neurotrauma. Journal of Neurotrauma.  2003, 20: 401-407.

 

 

Received on 18.09.2009

Accepted on 23.10.2009     

© A&V Publication all right reserved

Research J. Pharmacology and Pharmacodynamics 1(3) Nov. – Dec 2009; 99-103